US equities |
AAPL $343.67 ▲+0.49% MU $900.80 ▼-3.27% TSLA $365.81 ▲+0.93% NVDA $216.05 ▼-0.54% SPCX $144.86 ▼-2.53% MSFT $540.10 ▲+0.12% SNDK $1,350.11 ▼-3.21% AMZN $254.62 ▼-0.05%
FinancialContent

Articles published by Aileron Therapeutics, Inc.

News headline image
Aileron Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
From Aileron Therapeutics, Inc.
Via GlobeNewswire
Tickers ALRN
News headline image
Aileron Therapeutics to Present at Two Upcoming Investor Conferences
From Aileron Therapeutics, Inc.
Via GlobeNewswire
Tickers ALRN
News headline image
Aileron Therapeutics Announces Closing of Underwritten Registered Direct Offering of up to Approximately $40 Million
From Aileron Therapeutics, Inc.
Via GlobeNewswire
Tickers ALRN
News headline image
Aileron Therapeutics Announces Pricing of Underwritten Registered Direct Offering Priced At-The-Market Under Nasdaq Rules of up to Approximately $40 Million
From Aileron Therapeutics, Inc.
Via GlobeNewswire
Tickers ALRN
News headline image
Aileron Therapeutics Announces Positive Data from Cohort 1 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)
From Aileron Therapeutics, Inc.
Via GlobeNewswire
Tickers ALRN
News headline image
Aileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
From Aileron Therapeutics, Inc.
Via GlobeNewswire
Tickers ALRN
News headline image
Aileron Therapeutics Announces CEO Transition
From Aileron Therapeutics, Inc.
Via GlobeNewswire
Tickers ALRN
News headline image
Aileron Therapeutics and Pulmonary Care Experts To Discuss the Potential Implications of LTI-03 for Idiopathic Pulmonary Fibrosis in Virtual Key Opinion Leader Event
From Aileron Therapeutics, Inc.
Via GlobeNewswire
Tickers ALRN
News headline image
Aileron Therapeutics to Host Key Opinion Leader Event on February 15, 2024
From Aileron Therapeutics, Inc.
Via GlobeNewswire
Tickers ALRN
News headline image
Aileron Therapeutics Announces Termination of Phase 1b Breast Cancer Chemoprotection Trial and Exploration of Strategic Alternatives
From Aileron Therapeutics, Inc.
Via GlobeNewswire
Tickers ALRN
News headline image
Aileron Therapeutics Regains Compliance with Nasdaq Listing Requirements
From Aileron Therapeutics, Inc.
Via GlobeNewswire
Tickers ALRN
News headline image
Aileron Therapeutics Announces a 1-for-20 Reverse Stock Split
From Aileron Therapeutics, Inc.
Via GlobeNewswire
Tickers ALRN
News headline image
Aileron Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights
From Aileron Therapeutics, Inc.
Via GlobeNewswire
Tickers ALRN
News headline image
Aileron Therapeutics Presents Results from Phase 1 Study in Healthy Volunteers Demonstrating ALRN-6924 Induced Cell Cycle Arrest in Bone Marrow Stem Cells and Hair Follicles at EORTC-NCI-AACR International Conference
From Aileron Therapeutics, Inc.
Via GlobeNewswire
Tickers ALRN
News headline image
Aileron Therapeutics Announces Oral Presentation of Non-Clinical Data Demonstrating ALRN-6924 Protected Human Hair Follicles and Their Stem Cells from Chemotherapy-Induced Damage at the European Society for Dermatological Research Annual Meeting 2022
From Aileron Therapeutics, Inc.
Via GlobeNewswire
Tickers ALRN